Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit the Swiss pharma bought for $4.3 billion in 2019. | Roche has recently launched a “fundamental ...

This previously untreatable genetic disorder, which affects some two to three of every 10 million newborn babies, leads to ...

He said the company was ‘locked and loaded’ to start manufacturing the complex gene therapy product, but was a little bit more circumspect about whether Luxturna could make money.

Luxturna, a gene therapy for a rare disorder that causes vision loss, costs $425,000 per eye. Industry insiders assumed Zolgensma would cost more than Luxturna. But how much? There was what I ...

In connection with Spark’s overhaul, Roche will incur approximately $2.4 billion in goodwill impairment costs. This sum takes ...

In December 2017, the US Food & Drug Administration (FDA) approved Luxturna from Spark Therapeutics — the first gene therapy to win market approval in the US. Several other gene therapy programs ...

This approach yields a reasonable output of fully-assembled, gene therapy-ready rAAV particles ... including Spark Therapeutics’ Luxturna and a pair of other therapies now in phase 3 testing ...

The first NHS patients have started treatment with Novartis’ Luxturna, a gene therapy for a sight-robbing inherited disease, after the drugmaker agreed a discount on its £613,000 list price ...

Spark has the distinction of being the first company to receive FDA approval of a gene therapy treatment for an inherited disease. The product, Luxturna, was approved in late 2017 as a one-time ...

The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, March 10, 2025 /EINPresswire / -- How Has the Luxturna Gene Therapy Market Grown in Recent Years? The Luxturna gene therapy ...